Oncolytic viruses: A novel treatment strategy for breast cancer

Javanbakht, Mohammad; Tahmasebzadeh, Sanaz; Cegolon﻿﻿, Luca; Gholami, Nasrin; Kashaki, Mandana; Nikoueinejad, Hassan; Mozafari, Mohammad Reza; Mozaffari, Mahsa; Zhao, Shiqi; Khafaei, Mostafa; Izadi, Morteza; Fathi, Saeed; Akhavan‐Sigari, Reza

doi:10.1016/j.gendis.2021.11.011

Cited by 9 publications

(6 citation statements)

References 117 publications

(347 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study there were no significant side effects reported ( 54 ). Additionally, previous clinical trials reported side effects that were mild, completely reversible, and not causing an interruption in treatment, such as subfebrile temperature, pain in the location of the tumour, fatigue, sleepiness, and dyspepsia ( 55 ). Despite its registration in Latvia, Georgia, and Armenia, Rigvir was discontinued in mid-2019 due to manufacturing issues and then suspended for marketing authorization ( 60 ).…”

Section: Discussionmentioning

confidence: 99%

“…OV therapy is often combined with other modalities such as chemotherapy, immunotherapy, or targeted therapies. Evaluating potential interactions and cumulative toxicities of these combined approaches is essential to mitigate risks and enhance therapeutic outcomes ( 55 ).…”

Section: Discussionmentioning

confidence: 99%

“…HSV1716 was approved for clinical trials in Europe in 1996 and has been used with satisfying results in the treatment of glioblastoma multiforme, melanoma, and head and neck squamous cell carcinoma ( 54 ). T-vec, also known as IMLYGIC or OncoVEX GM-CSF, proved to be effective and safe in a few Phase 1 clinical trials in patients with refractory breast cancer ( 55 ). It has been suggested that the retention of ICP34.5 may be beneficial in some situations of IFN-dependent antiviral tumour status, as it can enhance the oncolytic effect and end the overall efficacy of OV.…”

Section: Types Of Viruses Used In Oncolytic Trialsmentioning

confidence: 99%

See 2 more Smart Citations

New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy

Chowaniec,

Ślubowska,

Mroczek

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Oncolytic virus (OV) therapy has emerged as a promising frontier in cancer treatment, especially for solid tumours. While immunotherapies like immune checkpoint inhibitors and CAR-T cells have demonstrated impressive results, their limitations in inducing complete tumour regression have spurred researchers to explore new approaches targeting tumours resistant to current immunotherapies. OVs, both natural and genetically engineered, selectively replicate within cancer cells, inducing their lysis while sparing normal tissues. Recent advancements in clinical research and genetic engineering have enabled the development of targeted viruses that modify the tumour microenvironment, triggering anti-tumour immune responses and exhibiting synergistic effects with other cancer therapies. Several OVs have been studied for breast cancer treatment, including adenovirus, protoparvovirus, vaccinia virus, reovirus, and herpes simplex virus type I (HSV-1). These viruses have been modified or engineered to enhance their tumour-selective replication, reduce toxicity, and improve oncolytic properties.Newer generations of OVs, such as Oncoviron and Delta-24-RGD adenovirus, exhibit heightened replication selectivity and enhanced anticancer effects, particularly in breast cancer models. Clinical trials have explored the efficacy and safety of various OVs in treating different cancers, including melanoma, nasopharyngeal carcinoma, head and neck cancer, and gynecologic malignancies. Notably, Talimogene laherparepvec (T-VEC) and Oncorine have. been approved for advanced melanoma and nasopharyngeal carcinoma, respectively. However, adverse effects have been reported in some cases, including flu-like symptoms and rare instances of severe complications such as fistula formation. Although no OV has been approved specifically for breast cancer treatment, ongoing preclinical clinical trials focus on four groups of viruses. While mild adverse effects like low-grade fever and nausea have been observed, the effectiveness of OV monotherapy in breast cancer remains insufficient. Combination strategies integrating OVs with chemotherapy, radiotherapy, or immunotherapy, show promise in improving therapeutic outcomes. Oncolytic virus therapy holds substantial potential in breast cancer treatment, demonstrating safety in trials. Multi-approach strategies combining OVs with conventional therapies exhibit more promising therapeutic effects than monotherapy, signalling a hopeful future for OV-based breast cancer treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Types Of Viruses Used In Oncolytic Trialsmentioning

confidence: 99%

See 1 more Smart Citation

New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy

Chowaniec,

Ślubowska,

Mroczek

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Oncolytic viruses are regarded as a promising tool for the treatment of a variety of tumors [ 10 , 12 , 13 , 14 , 56 ]. Among various types of cancer, GBM represents one of the most challenging targets, as patients with this type of brain tumors have poor prognosis due to low efficacies of treatment, very high rates of relapse, and severe side effects of the treatment [ 3 , 4 , 6 , 7 ].…”

Section: Discussionmentioning

confidence: 99%

“…Oncolytic viruses represent a rediscovered option to suppress the growth of GBM and other solid tumors [ 10 , 11 , 12 , 13 , 14 ]. Throughout the history of vaccine development and studying viral infection, spontaneous cancer regression and even remission upon viral infection were observed [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

2-Deoxyglucose, an Inhibitor of Glycolysis, Enhances the Oncolytic Effect of Coxsackievirus

Vorobyev

Kochetkov

Chumakov

et al. 2022

Cancers

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is one of the most common types of brain tumor. Despite intensive research, patients with GBM have a poor prognosis due to a very high rate of relapse and significant side effects of the treatment, with a median survival of 14.6 months. Oncolytic viruses are considered a promising strategy to eliminate GBM and other types of cancer, and several viruses have already been introduced into clinical practice. However, identification of the factors that underly the sensitivity of tumor species to oncolytic viruses or that modulate their clinical efficacy remains an important target. Here, we show that Coxsackievirus B5 (CVB5) demonstrates high oncolytic potential towards GBM primary cell species and cell lines. Moreover, 2-deoxyglucose (2DG), an inhibitor of glycolysis, potentiates the cytopathic effects of CVB5 in most of the cancer cell lines tested. The cells in which the inhibition of glycolysis enhanced oncolysis are characterized by high mitochondrial respiratory activity and glycolytic capacity, as determined by Seahorse analysis. Thus, 2-deoxyglucose and other analogs should be considered as adjuvants for oncolytic therapy of glioblastoma multiforme.

show abstract